HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sectionectomy is suitable for patients with T2 hepatocellular carcinoma according to the modified international union against cancer TNM Classification.

AbstractBACKGROUND/AIMS:
The effectiveness of systematized hepatectomy in the modified International Union Against Cancer (UICC) staging classification for hepatocellular carcinoma (HCC) has not been clarified in detail.
METHODS:
We retrospectively studied 406 patients with UICC T1 HCC and 124 patients with T2 HCC who underwent initial curative hepatectomy from 1994 through 2003. Outcomes after sectionectomy or larger resection and segmentectomy or smaller resection for patients with T1 HCC and T2 HCC were examined.
RESULTS:
The overall recurrence-free survival rate and survival rate of sectionectomy or larger resection at 5 years (45 and 79%, respectively) did not significantly differ from those of segmentectomy or smaller resection (38 and 81%, respectively) in patients with T1 HCC. However, in patients with T2 HCC, the 5-year recurrence-free survival rate and survival rate after sectionectomy or larger resection (37 and 71%, respectively) were significantly different from those after segmentectomy or smaller resection (6%: p < 0.0001, and 35%: p = 0.0027, respectively). Multivariate analysis showed sectionectomy or larger resection to be a significant independent prognostic factor for recurrence-free survival and survival in patients with T2 HCC.
CONCLUSIONS:
Sectionectomy or larger resection prevents intrahepatic recurrence of HCC and prolongs survival in patients with T2 HCC.
AuthorsShun-Ichi Ariizumi, Satoshi Katagiri, Hideo Katsuragawa, Yoshihito Kotera, Masakazu Yamamoto
JournalDigestive surgery (Dig Surg) Vol. 24 Issue 5 Pg. 342-8 ( 2007) ISSN: 0253-4886 [Print] Switzerland
PMID17785977 (Publication Type: Journal Article)
Topics
  • Anatomy, Cross-Sectional (methods)
  • Carcinoma, Hepatocellular (mortality, pathology, surgery)
  • Epidemiologic Methods
  • Female
  • Hepatectomy (methods, mortality)
  • Humans
  • Liver Neoplasms (mortality, pathology, surgery)
  • Male
  • Neoplasm Recurrence, Local (prevention & control)
  • Neoplasm Staging (standards)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: